Diseases related to undergoing gynecological laparoscopic surgery
Conditions
Interventions
A Group:Loading dose of 0.1 ug/kg sufentanil + 1 ug/kg anrikefon
48-hour analgesic dose of 2 ug/kg + 6 ug/kg sufentanil
patient-controlled bolus of 2 ml with a lockout time of 15 min
B Group:Loading dose of 0.1 ug/kg sufentanil
48-hour analgesic dose of 2 ug/kg sufentanil
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients scheduled for elective gynecological laparoscopic surgery; 2. ASA physical status I-III; 3. Age 18-65 years; BMI 18-35 kg/m^2; 4. Ethical compliance, voluntary participation with signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe cardiac, pulmonary, hepatic, or renal dysfunction; 2. History of psychiatric disorders (e.g., dementia, schizophrenia) or long-term use of psychotropic medications, chronic analgesic use, alcoholism, or drug allergies; 3. Severe infection; 4. Inability to communicate due to language barriers, hearing impairment, or neurological deficits (e.g., stroke); 5. Preoperative PaO2 <60 mmHg or SpO2 <90%; 6. Participation in another clinical drug trial within the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sufentanil consumption within 48 hours postoperatively in Group A versus Group B; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of adverse events (nausea, vomiting, pruritus, somnolence, respiratory depression) within 48 hours postoperatively;Number of rescue analgesic administrations and dose within 48 hours postoperatively;NRS scores at 0.5, 2, 6, 12, 24, and 48 hours postoperatively;Baseline demographic and clinical characteristics including age, sex, height, weight, ASA classification, and comorbidities;Safety outcomes including nausea, vomiting, pruritus, somnolence, and respiratory depression; | — |
Countries
China
Contacts
Public ContactSun Linglu
Anqing Municipal Hospital
Outcome results
None listed